Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ridaforolimus in relapsed/refractory hematologic malignancies
NCT00086125Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Jun 2004
- Primary completion
- Jun 2006
- Modality
- Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ridaforolimus in leukemia, myelodysplastic syndrome (MDS), primary myelofibrosis (PMF) and 1 more, sponsored by Merck & Co. Primary endpoint: Response Rate. Started Jun 2004; status: completed.
02
Drugs
ridaforolimus
03
Conditions
leukemiamyelodysplastic syndrome (MDS)primary myelofibrosis (PMF)lymphoma
Beyond the preview
Go deeper on NCT00086125.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00086125.